alexa Phage Therapy: Promising For H.pylori Infection | OMICS International
ISSN: 2327-5073
Clinical Microbiology: Open Access
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Phage Therapy: Promising For H.pylori Infection

Qing-Hua Zou* and Wen Wei

Department of Microbiology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China

*Corresponding Author:
Qing-Hua Zou
Department of Microbiology
Peking University Health Science Center, No.38 Xue Yuan Road
Haidian District, Beijing, 100191 ,China
Tel: +861082802807
E-mail: [email protected]

Received Date: April 22, 2013; Accepted Date: April 25, 2013; Published Date: April 27, 2013

Citation: Zou QH, Wei W (2013) Phage Therapy: Promising For H.pylori Infection. Clin Microbial 2:112. doi: 10.4172/2327-5073.1000112

Copyright: © 2013 Zou QH, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Clinical Microbiology: Open Access

Helicobacter pylori (H.pylori) is a widely distributed human pathogen with high prevalence in human population. Many researches showed H.pylori infection is closely related with chronic gastritis, ganstric duodenal ulcer, mucosa associated diseases such as lymphoma and gastric cancer [1,2]. It has been classified as the class I carcinogen in 1994 by the World Health Organization and the International Agency for Research on Cancer consensus group [3]. The prevalence in the human population is 50-80%, with an increasing rate of 1-2% annually. About 12 million new cases emerged every year. H.pylori infection has become an extrusive public problem.

Unlike more common infection, H. pylori are sensitive to only a few medications, including PPI, amoxicillin, clarithromycin, metronidazole and so on. Different combinations of these antibiotics such as PPI combined with two antibiotics have been applied to eradicate the bacteria. However, they usually cannot give an acceptable eradication rate and increasing antibiotic resistance is becoming a problem [4]. At the same time upleasant side effects usually generated along with antibiotic therapies. For example, PPI can change the acid environment in the stomach, however the effect varies in different individuals, and it can lead to liver and kidney damage and thus often have poor compliance for patients [5]. Since the effects of antibiotics cannot meet our needs and multidrug-resistant H. pylori increases greatly, new therapies for H.pylori is in need.

Phages are reported as the most abundant organisms on earth and are ubiquitous in the nature. Phage therapy uses phages or their products as biological factors to treat or prevent bacterial infectious diseases. As early as 1917, prelimilary research showed phages can be used as therapeutic agents for bacterial disease [6]. Thereafter, a variety of infections including: gastroenteritis, sepsis, suppurative wounds, dermatitis, osteomelitis, emphysemas and pneumonia were cured by phage therapy in humans. In these experiments, the success rates were about 80 to 95 percent and there was no undesirable reaction [7]. Recent studies also showed many antibiotic-resistant infections such as Bacillus anthracis, Staphylococci, Escherichia, Klebsiella and Propionibacterium acnes were successfully treated by phage therapy [8-11]. Phage therapy has the advantages other biological agents do not have, such as high specificity for target bacterium; safe to be utilized clinically; few side effects; the frequency of phage mutation is much higher than that of bacteria, so if a phage-resistant bacterium emerges, the phage responds quickly [12].

In recent years, more and more researchers began to study H. pylori phages which may be possible prophylactic and alternative therapeutic treatment. The first H. pylori phages was reported by Schimd et al who isolated a H. pylori strain which can produce phages in vivo [13]. This phages can lysogenized H. pylori strain SchReck 290 rather than virulent to the bacteria. In 1993, Heintschel et al documented the isolation, propagation, lytic cycle, morphology, and genome composition of HP1 phage, recovered from H. pylori strain SchReck 290 [14]. In 2008, Vale et al. described the release of phage-like particles by H. pylori following UV induction [15]. In 2011, Lehours et al. discovered that temperate phage of the Siphoviridae family was released from H. pylori strain B45 following induction [16]; Wan et al. isolated a wild-type virulent phage of H. pylori and studied its simulated treatments of gastrointestinal H. pylori in vitro [17]. Other studies characterized H. pylori phage 1961P and KHP30 and found they are dissimilar to any previously sequenced phages and should be a new type of phages [18,19]. All these studies bring new opportunity for H. pylori phage discoveries and phage therapy.

Considering the great troubles such as low eradication rate and antibiotic resistance in H. pylori therapy, lytic and virulent phages to H. pylori appears promising in the future. We believe that with more studies on H. pylori phages, we can get a better understanding to the treatment of H. pylori. Phage therapies will provide a new effective treatment options for H. pylori infections.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 11959
  • [From(publication date):
    June-2013 - Jun 20, 2018]
  • Breakdown by view type
  • HTML page views : 8141
  • PDF downloads : 3818

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7